Cargando…
Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab
BACKGROUND: Giant cell tumor of bone is a benign, locally aggressive neoplasm. Surgical resection is the preferred treatment method. However, for cases in which resection poses an increased risk to the patient, denosumab (anti-RANKL monoclonal antibody) is considered. Secukinumab is an anti-IL-17 an...
Autores principales: | Chandler, Andrew, Bartelstein, Meredith K., Fujiwara, Tomohiro, Antonescu, Cristina R., Healey, John H., Vaynrub, Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015053/ https://www.ncbi.nlm.nih.gov/pubmed/33794838 http://dx.doi.org/10.1186/s12891-021-04182-z |
Ejemplares similares
-
Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022) -
Periacetabular reconstruction following limb-salvage surgery for pelvic sarcomas
por: Fujiwara, Tomohiro, et al.
Publicado: (2021) -
Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019) -
Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab
por: Hakozaki, Michiyuki, et al.
Publicado: (2014) -
Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
por: Kammüller, Michael, et al.
Publicado: (2017)